Perrigo Company plc (NYSE:PRGO) Receives $19.33 Average Price Target from Brokerages

Shares of Perrigo Company plc (NYSE:PRGO) have been assigned a consensus rating of “Hold” from the six brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $19.3333.

Several research firms recently weighed in on PRGO. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Canaccord Genuity Group cut their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Weiss Ratings cut shares of Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th.

Perrigo Stock Performance

NYSE:PRGO opened at $10.98 on Wednesday. The stock has a market cap of $1.52 billion, a P/E ratio of -0.84, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The firm’s fifty day simple moving average is $11.18 and its 200 day simple moving average is $12.45. Perrigo has a twelve month low of $9.23 and a twelve month high of $28.43. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $841.80 million for the quarter, compared to analysts’ expectations of $1.04 billion. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The firm’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, research analysts predict that Perrigo will post 2.11 EPS for the current year.

Perrigo Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th will be given a dividend of $0.29 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.16 annualized dividend and a yield of 10.6%. Perrigo’s dividend payout ratio (DPR) is currently -8.85%.

Hedge Funds Weigh In On Perrigo

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRGO. EverSource Wealth Advisors LLC lifted its position in Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after buying an additional 1,014 shares during the period. Geneos Wealth Management Inc. lifted its position in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after buying an additional 786 shares during the period. UMB Bank n.a. lifted its position in Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after buying an additional 1,213 shares during the period. Meeder Asset Management Inc. purchased a new position in Perrigo during the fourth quarter valued at $28,000. Finally, CWM LLC lifted its position in Perrigo by 230.0% during the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after buying an additional 1,527 shares during the period. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.